Foamix Pharmaceuticals Stock Company Profile

Description

Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne and other skin conditions in the United States, Germany, France, and Israel. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by methicillin-resistant staphylococcus aureus. The company is also developing FMX103, a version of its minocycline foam FMX101, which is in Phase II clinical trial for the treatment of rosacea; and FDX104 that has completed Phase II clinical trail for the treatment of chemotherapy-induced rash. It has development and license agreements with Bayer HealthCare AG, Merz Pharmaceuticals, LLC, and Allergan plc. The company was founded in 2003 and is headquartered in Rehovot, Israel.